StemCells (STEM) partners with Edinburgh, UK-based R Biomedical to develop and commercialize a...
StemCells (STEM) partners with Edinburgh, UK-based R Biomedical to develop and commercialize a range of cell lines and reagents to be used in stem cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under STEM's SC Proven brand.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs